An Open-Label Pilot Study of Efficacy and Safety of 2% Curcuma aeruginosa Roxb. Extract Cream in the Treatment of Mild to Moderate Facial Seborrheic Dermatitis

Authors: Kulaya Wimolwat, Panlop Chakravitthamrong, Neti Waranuch

Abstract:

Background: Seborrheic dermatitis is a common chronic skin condition affecting the face, scalp, chest, and trunk. The cause of seborrheic dermatitis is still unknown. Sebum production, lipid composition, hormone levels, and Malassezia species have been suggested as important factors in the development of seborrheic dermatitis. Curcuma aeruginosa Roxb. extract-containing cream with anti-inflammatory and anti-androgenic properties may be beneficial for treating mild to moderate facial seborrheic dermatitis. Objectives: We evaluated the efficacy and safety of 2% C. aeruginosa Roxb. extract-containing cream in the treatment of mild to moderate seborrheic dermatitis. Methods: This was a prospective, open-label, and non-comparative study. Ten adult patients clinically diagnosed with mild to moderate seborrheic dermatitis were enrolled in a four-week study. The 2% C. aeruginosa Roxb. cream was applied twice daily to a lesional area on the face for four weeks. The Scoring Index (SI) ranking system on days 14 and 28 was compared with that at baseline to determine the efficacy of treatment. The adverse events (burning sensation and erythema) were evaluated on days 14 and 28 to determine the safety of the treatment. Results: Significant improvement was observed in the reduction of the mean SI at day 14 (2.9) and 28 (1.4) compared to that at baseline (4.9). An adverse reaction was observed on day 14 (mild erythema 20% and mild burning sensation 10%) and was resolved by the end of the study. Conclusion: This open-label pilot study has shown that there was a significant improvement in the severity in these seborrheic patients and most reported they were satisfied with it. Reported adverse events were all mild.

Keywords: Anti-androgenic, antifungals, anti-inflammatory, Curcuma aeruginosa, seborrheic dermatitis, efficacy, safety.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1127583

References:

[1] G. W. Clark, S. M. Pope, and K. A. Jaboori, “Diagnosis and treatment of seborrheic dermatitis,” Am. Fam. Physician. vol. 91(3), pp. 85–190, 2015
[2] A. K. Gupta, R. Bluhm, J. O. Barlow, A. B. Fleischer, Jr., and S. R. Feldman, “Prescribing practices for seborrheic dermatitis vary with the physician's specialty: implications for clinical practice,” J. Dermatol. Treat. vol. 15(4), pp. 208–213, 2004.
[3] A. K. Gupta, M. Richardson, and M. Paquet, “Systematic review of oral treatments for seborrheic dermatitis,” J. Eur. Acad. Dermatol. Venereol. vol. 28(1), pp. 16–26, 2014.
[4] G. K. Kim, “Seborrheic dermatitis and Malassezia species: how are they related?” J. Clin. Aesthet. Dermatol. 2009; 2(11):14-17.
[5] A. K. Gupta, S. E. Madzia, and R. Batra, “Etiology and management of Seborrheic dermatitis,” Dermatology. vol. 208(2), pp. 89–93, 2004.
[6] J. D. Stratigos, C. Antoniou, A. Katsambas, K. Bohler, P. Fritsch, A. Schmolz, et al., “Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study,” J. Am. Acad. Dermatol. vol. 19 (5 Pt 1), pp. 850–853, 1988.
[7] A. Firooz, A. Solhpour, F. Gorouhi, M. Daneshpazhooh, K. Balighi, K. Farsinejad, et al., “Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial,” Arch. Derm. vol. 142(8), pp. 1066–1067, 2006.
[8] M. Goldust, E. Rezaee, S. Masoudnia, and R. Raghifar, “Clinical study of sertaconazole 2% cream vs. hydrocortisone 1% cream in the treatment of seborrheic dermatitis,” Ann. Parasitol. vol. 59(3), pp. 119–123, 2013.
[9] L. Naldi, “Seborrhoeic dermatitis,” BMJ Clin. Evid. vol. 2010, 2010.
[10] A. K. Gupta and R. Bluhm, “Seborrheic dermatitis,” J. Eur. Acad. Dermatol. Venereol. vol. 18(1), pp. 13–26; quiz 19–20, 2004.
[11] C. F. Hossain, M. Al-Amin, A. S. Sayem, I. H. Siragee, A. M. Tunan, F. Hassan, et al., “Antinociceptive principle from Curcuma aeruginosa,” BMC Complement. Altern. Med. vol. 15, pp. 191, 2015.
[12] N. Suphrom, G. Pumthong, N. Khorana, N. Waranuch, N. Limpeanchob, and K. Ingkaninan, “Anti-androgenic effect of sesquiterpenes isolated from the rhizomes of Curcuma aeruginosa Roxb.,” Fitoterapia. vol. 83(5), pp. 864–871, 2012.
[13] G. Pumthong, P. Asawanonda, S. Varothai, V. Jariyasethavong, D. Triwongwaranat, P. Suthipinittharm, et al., “Curcuma aeruginosa, a novel botanically derived 5alpha-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study,” J. Dermatol. Treat. vol. 23(5), pp. 385–392, 2012.
[14] Kamazeri TS, Samah OA, Taher M, Susanti D, Qaralleh H., “Antimicrobial activity and essential oils of Curcuma aeruginosa, Curcuma mangga, and Zingiber cassumunar from Malaysia,” Asian Pacific journal of tropical medicine. vol. 5(3), pp. 202-209, 2012.
[15] Aspollah M, Suhaila, S., Nordin, S., Rahmani, L. M., Muse, R., Yusuf, U. K., Riyanto, S., “Chemical constituents and bioactivity of Curcuma aeruginosa Roxb.,” Natural Product Sciences. vol. 3(13), pp. 175-179, 2007.
[16] Kitamura C, Nagoe T, Prana MS, Agusta A, Ohashi K, Shibuya H., “Comparison of Curcuma sp. in Yakushima with C. aeruginosa and C. zedoaria in Java by trnK gene sequence, RAPD pattern and essential oil component,” Journal of Natural Medicines. vol. 61(3), pp. 239-243, 2007.
[17] Angel GR, Vimala, B., Nambisan, B., “Phenolic content and antioxidant activity in five underutilized starchy Curcuma species,” International Journal of Pharmaceutical and Phytopharmacological Research. vol. 2(4), pp.69-73, 2012.
[18] Jantan I, Rafi IA, Jalil J., “Platelet-activating factor (PAF) receptor-binding antagonist activity of Malaysian medicinal plants,” Phytomedicine. vol. 12(1-2), pp. 88-92, 2005.
[19] Moon-ai W, Niyomploy P, Boonsombat R, Sangvanich P, Karnchanatat A., “A superoxide dismutase purified from the rhizome of Curcuma aeruginosa Roxb. as inhibitor of nitric oxide production in the macrophage-like RAW 264.7 cell line,” Applied biochemistry and biotechnology. vol 166(8), pp. 2138-2155, 2012.
[20] Reanmongkol W, Subhadhirasakul, S., Khaisombat, N., Fuengnawakit, P., Jantasila, S. and Khamjun, A., “Investigation the antinociceptive, antipyretic and anti-inflammatory activities of Curcuma aeruginosa Roxb. extracts in experimental animals,” Songklanakarin J Sci Technol. vol. 5 (28), pp. 999-1008, 2006.
[21] Liu Y, Roy SS, Nebie RH, Zhang Y, Nair MG., “Functional food quality of Curcuma caesia, Curcuma zedoaria and Curcuma aeruginosa endemic to Northeastern Indi,” Plant foods for human nutrition (Dordrecht, Netherlands). vol. 68(1), pp. 72-77,2013.
[22] Matangkasombut OP, Suckvanichsilp, N., Somanapan, A., “Postcoital contraceptive effect of Curcuma aeruginosa Roxb. in albino rat,” Journal of the ASEAN Federation of Endocrine Societies. vol. (3), pp.117–118, 1983.